| Autor: |
Delgado, Dayana A.1, Chernoff, Meytal1, Lei Huang2, Lin Tong1, Lin Chen1, Jasmine, Farzana1, Shinkle, Justin1, Cole, Shelley A.3, Haack, Karin3, Kent, Jack3, Umans, Jason4, Best, Lyle G.5, Nelson, Heather6, Griend, Donald Vander7, Graziano, Joseph8, Kibriya, Muhammad G.1, Navas-Acien, Ana8, Karagas, Margaret R.9, Ahsan, Habibul1,10,11,12, Pierce, Brandon L.1,10,11 brandonpierce@uchicago.edu |
| Předmět: |
|
| Zdroj: |
Environmental Health Perspectives. Apr2021, Vol. 129 Issue 4, p047007-1-047007-11. 11p. 1 Diagram, 4 Charts, 1 Graph. |
| Abstrakt: |
BACKGROUND: Common genetic variation in the arsenic methyltransferase (AS3MT) gene region is known to be associated with arsenic metabolism efficiency (AME), measured as the percentage of dimethylarsinic acid (DMA%) in the urine. Rare, protein-altering variants in AS3MT could have even larger effects on AME, but their contribution to AME has not been investigated. OBJECTIVES: We estimated the impact of rare, protein-coding variation in AS3MT on AME using a multi-population approach to facilitate the discovery of population-specific and shared causal rare variants. METHODS: We generated targeted DNA sequencing data for the coding regions of AS3MT for three arsenic-exposed cohorts with existing data on arsenic species measured in urine: Health Effects of Arsenic Longitudinal Study (HEALS, 푛 = 2,434), Strong Heart Study (SHS, 푛 = 868), and New Hampshire Skin Cancer Study (NHSCS, 푛 = 666). We assessed the collective effects of rare (allele frequency <1%), protein-altering AS3MT variants on DMA%, using multiple approaches, including a test of the association between rare allele carrier status (yes/no) and DMA% using linear regression (adjusted for common variants in 10q24.32 region, age, sex, and population structure). RESULTS: We identified 23 carriers of rare-protein-altering AS3MT variant across all cohorts (13 in HEALS and 5 in both SHS and NHSCS), including 6 carriers of predicted loss-of-function variants. DMA% was 6–10% lower in carriers compared with noncarriers in HEALS [ß=-9.4 (95% CI: -13.9, -4.8)], SHS [ß=-6.9 (95% CI: -13.6, -0.2)], and NHSCS [ß=-8.7 (95% CI: -15.6, -2.2)]. In meta-analyses across cohorts, DMA% was 8.7% lower in carriers [ß=-8.7 (95% CI: -11.9, -5.4)]. DISCUSSION: Rare, protein-altering variants in AS3MT were associated with lower mean DMA%, an indicator of reduced AME. Although a small percentage of the population (0.5–0.7%) carry these variants, they are associated with a 6–10% decrease in DMA% that is consistent across multiple ancestral and environmental backgrounds. [ABSTRACT FROM AUTHOR] |
| Databáze: |
GreenFILE |
| Externí odkaz: |
|
